What Is Herpesvirus 1, Human (HSV-1)? Uses, Medications, and What You Need to Know in 2026

Herpesvirus 1, Human — commonly known as herpes simplex virus type 1 (HSV-1) — is one of the most widespread viral infections in the world. The World Health Organization estimates that 3.7 billion people under the age of 50 (approximately 67% of the global population) are infected with HSV-1. Despite its prevalence, many people don't fully understand the virus, its symptoms, or the medications used to manage it. This comprehensive guide explains everything you need to know.

What Is HSV-1?

HSV-1 is a member of the Herpesviridae family, specifically the alpha-herpesvirus subfamily. It is a double-stranded DNA virus that has co-evolved with humans for millennia. The virus is distinct from HSV-2, though both types can cause oral and genital herpes. HSV-1 is the primary cause of oral herpes (cold sores) and is increasingly responsible for a growing proportion of genital herpes cases, especially among young people.

A key characteristic of herpesviruses is latency: after initial infection, HSV-1 retreats to sensory nerve ganglia (nerve clusters near the spine or brainstem) and remains there for life. The virus can reactivate — triggered by stress, illness, sun exposure, hormonal changes, or immune suppression — causing recurrent outbreaks at or near the original site of infection.

What Conditions Does HSV-1 Cause?

HSV-1 can cause a range of clinical conditions depending on the site of infection and immune status:

• Herpes labialis (cold sores): The most common manifestation — painful blisters around the mouth and lips
• Genital herpes: HSV-1 now accounts for a growing proportion of new genital herpes diagnoses, especially in young adults and through oral sex
• Herpetic whitlow: HSV-1 infection of the finger, common in healthcare workers and children who touch their mouths
• Herpes simplex keratitis: Eye infection that can cause corneal scarring and vision loss if untreated; a leading cause of infectious blindness in developed countries
• Herpes simplex encephalitis: Rare but potentially fatal brain infection; most commonly caused by HSV-1
• Neonatal herpes: Severe, potentially fatal HSV infection in newborns, transmitted during delivery

How Is HSV-1 Transmitted?

HSV-1 spreads primarily through direct contact with infected secretions or lesions:

• Oral contact (kissing, sharing utensils or drinks) — primary route for oral HSV-1
• Oral-genital contact — leading cause of new genital HSV-1 infections
• Asymptomatic viral shedding — the virus can be transmitted even when no visible sores are present

FDA-Approved Medications for HSV-1 in 2026

There is currently no cure for HSV-1, and no approved vaccine is available. However, FDA-approved antiviral medications can dramatically reduce outbreak frequency, severity, duration, and the risk of transmission:

• Acyclovir (Zovirax): The original antiviral; available in oral (200 mg, 400 mg, 800 mg), IV, and topical forms. Requires dosing 2–5 times daily depending on indication.
• Valacyclovir (Valtrex): Prodrug of acyclovir with 3–5x better bioavailability; available in 500 mg and 1,000 mg oral tablets. Dosed once or twice daily — far more convenient than acyclovir.
• Famciclovir (Famvir): Prodrug of penciclovir; available in 125 mg, 250 mg, and 500 mg oral tablets. Long intracellular half-life makes it effective with less frequent dosing.

Episodic vs. Suppressive Therapy: Which Is Right for You?

There are two main treatment approaches for recurrent HSV-1:

• Episodic therapy: Taking antiviral medication at the first sign of an outbreak (tingling, itching) for 1–5 days. Best for patients with infrequent, predictable outbreaks. Reduces duration and severity but does not prevent the outbreak entirely.
• Suppressive therapy: Taking antiviral medication daily, regardless of outbreaks. Reduces outbreak frequency by 70–80%, decreases transmission risk to partners, and improves quality of life. Best for patients with ≥6 outbreaks per year or who are in a discordant relationship.

Is There a Cure or Vaccine for HSV-1?

As of 2026, there is no approved cure for HSV-1 and no commercially available vaccine. However, research is advancing on multiple fronts: helicase-primase inhibitors (HPIs) represent a new antiviral class with different mechanisms than nucleoside analogues; CRISPR-based gene editing approaches are in early research; and several HSV vaccine candidates are in clinical trials. Current antiviral therapy effectively manages symptoms but does not eliminate the virus from the body.

Finding HSV-1 Antiviral Medications in Stock

Oral HSV-1 antivirals are generally available, but spot shortages at individual pharmacies can occur. If your pharmacy is out of stock, use medfinder to find nearby pharmacies with your medication in stock. For a current update on supply, see our HSV-1 antiviral shortage update for 2026.